Loading...
Genfit S.A.
GNFTF•PNK
Healthcare
Biotechnology
$3.72
$0.00(0.00%)

Financial performance has remained strong, with revenue growing from $11.48M in Q2 2023 to $61.10M in Q2 2024. Gross profit continued to perform well, with margins at 99% in the latest quarter. Operating income reached $31.22M in Q2 2024, holding a steady 51% margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at $32.008M. Net income rose to $30.31M, keeping EPS at $0.61. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan